TITLE: Antivirals for Treatment and Prophylaxis for Pandemic H1N1 and H5N1 Influenza: Cost-Effectiveness

DATE: 23 November 2010

RESEARCH QUESTION

What is the cost-effectiveness of antivirals for treatment and prophylaxis for pandemic H1N1 and H5N1 influenza?

KEY MESSAGE

Two economic evaluations on prophylaxis and antiviral therapies for pandemic influenza were identified.

METHODS

A limited literature search was conducted on key health technology assessment resources, including OVID Medline, Embase and PubMed, The Cochrane Library (Issue 11, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, EuroScan, international health technology agencies, and a focused Internet search. The search was limited to English language articles published between Jan 1, 2000 and Nov 11, 2010. Filters were applied to limit the retrieval to economic studies.

RESULTS

Two economic evaluations pertaining to the antiviral prophylaxis and therapies for pandemic influenza were identified. Additional articles of potential interest can be found in the appendix.

Economic evaluations


PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
[www.cadth.ca]
APPENDIX – FURTHER INFORMATION:

Review articles